Approval decisions and trial readouts can double a stock overnight. How we build a catalyst calendar and size around binary events.
Few corners of the market offer the raw explosiveness of clinical-stage biotech. A single trial readout or FDA decision can double a stock — or cut it in half — in a single session. That asymmetry is the attraction and the danger.
Build a catalyst calendar
The professionals do not guess; they map. PDUFA dates (the FDA's decision deadlines), Phase 2 and Phase 3 data readouts, and conference presentations are all knowable in advance. Building a calendar of upcoming binary events lets you position deliberately rather than reacting to headlines.
Respect the binary
These are, quite literally, coin-flip events with fat tails. That demands a different risk discipline: small position sizes, an understanding that a failed trial can be near-total loss, and never risking money you cannot afford to see cut in half overnight. Some traders prefer to own a basket rather than bet the farm on one readout.
The bottom line
Catalyst biotech is high-risk, high-reward and unforgiving of sloppy risk management. Map the calendar, size for the downside, and treat every binary as exactly that. Done with discipline, it can be one of the most rewarding niches in the market.
Want ideas like this every week?
Join the free Breakout Brief — the setups, sectors and signals we are watching.